{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.4","upperLimit":"29.0","value":"22.2"},{"groupId":"OG001","lowerLimit":"21.3","upperLimit":"34.7","value":"27.6"},{"groupId":"OG002","lowerLimit":"1.9","upperLimit":"8.6","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"179"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who had a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) as assessed using RECIST 1.1. Analysis of ORR was not planned or conducted for the switch-to-pembrolizumab treatment groups. The percentage of participants who experienced a CR or PR is presented. This was the final analysis for ORR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were initially randomized to receive pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"OG002","title":"Investigator-Choice Chemotherapy (ICC)"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all randomized participants. Participants were included in the initial treatment group to which they were randomized for the efficacy analysis.","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (Through Final Analysis database cutoff date of 16-Nov-2015)","title":"Overall Response Rate (ORR) - Initial Treatment Period","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}